|cannabis||adolescent use,depression via review||Effects of Adolescent Cannabis Use on Motivation and Depression: a Systematic Review||Aug 2019|
|Heavy adolescent cannabis use is associated with poorer educational outcomes and increased levels of depressive symptoms. The role of depression in how cannabis may affect motivation, broadly, is not yet clear, as most studies have not examined associations among all three constructs.|
|cannabis||anxiety,pain,depression in humans via survey (n=3341)||The Association between Cannabis Product Characteristics and Symptom Relief||Feb 2019|
|Patients showed an average symptom improvement of 3.5 (SD = 2.6) on an 11-point scale across the 27 measured symptom categories. Dried flower was the most commonly used product and generally associated with greater symptom relief than other types of products.|
|Linalool,Pinene||depression in mice via experiment||antidepressant activity of Litsea glaucescens essential oil: Identification of Beta-pinene and linalool as active principles||Sept 2012|
Ingestion Method: 100 and 300 mg/Kg.|
L. glaucescens essential oil showed antidepressant activity, beta--pinene and linalool were identified as its active principles. These results support the use of L. glaucescens in Mexican Traditional Medicine for the treatment of sadness.
|Limonene,Phellandrene||pain,depression in rats via experiment||Antihyperalgesic and antidepressive actions of (R)-(+)-limonene, Alpha-phellandrene, and essential oil from Schinus terebinthifolius fruits in a neuropathic pain model.||July 2015|
|Together, the results of the present work show that essential oil of S. terebinthifolius and compounds present in this oil, including (R)-(+)-limonene and alpha--phellandrene, exhibit antihyperalgesic effects against mechanical hyperalgesia, and are antidepressive,|
|Caryophyllene||depression,anxiety in mice||Beta-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice||Aug 2014|
Ingestion Method: 50mg/kg|
Taken together, these preclinical results suggest that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety and depression. The possibility that BCP may ameliorate the symptoms of these mood disorders offers exciting prospects for future studies.
|Linalool,Pinene||depression in mice||Linalool and Beta-pinene exert their antidepressant-like activity through the monoaminergic pathway.||May 2015|
|Our results indicate that linalool and beta--pinene produce an antidepressant-like effect through interaction with the monoaminergic system.|
|CBD||depression in rats via experiment||Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors.||Apr 2016|
Ingestion Method: 10-60 nmol injection|
Action Pathway: 5HT1A,CB1
CBD (PL: 10-60 nmol; IL:45-60 nmol) and 8-OH-DPAT (10 nmol) administration significantly reduced the immobility time in the FST, without changing locomotor activity in the OFT
|CBD||depression in mice||Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex.||Jun 2018|
Ingestion Method: 7-30 mg/kg|
Action Pathway: BDNF
These results indicate that CBD induces fast and sustained antidepressant-like effect in distinct animal models relevant for depression. These effects may be related to rapid changes in synaptic plasticity in the mPFC through activation of the BDNF-TrkB signaling pathway. The data support a promising therapeutic profile for CBD as a new fast-acting antidepressant drug.
|Caryophyllene||diabetes,pain,depression in mice via experiment||Beta-Caryophyllene, a Natural Sesquiterpene, Attenuates Neuropathic Pain and Depressive-Like Behavior in Experimental Diabetic Mice||Mar 2019|
Ingestion Method: oral 10 mg/kg/60 ?L|
Our data using an orally chronic BCP administration in the STZ challenged mice to suggest that glycemia, diabetes-related NP, and depressive-like behavior could be prevented/reduced by dietary BCP.
|cannabis||pain,anxiety,depression in humans via review||Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis||Jun 2019|
|Positive Meta-analytic results indicated that pain (64%), anxiety (50%), and depression/mood (34%) were common reasons for medical cannabis use. No evidence for publication bias was detected, despite heterogeneity in prevalence rates.|